Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fountain Medical Development Ltd.

Latest From Fountain Medical Development Ltd.

We Are Family: Why Recent Deals Show China And US Won’t Part Long

Recent deals linking Chinese and foreign firms indicate new and bolder views on China’s prospects for cutting-edge oncology and rare disease treatments, helped by recent regulatory changes, but a mix of factors is still at play, veteran executives say.

China Research & Development

Closer To Home: Hong Kong Takes On Nasdaq For China Biotech IPOs

Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

Financing Biologics

How China Regulatory Reforms Ring In International Biotechs' New Year

Just how much regulatory reforms help fuel biotech investment rush in China? Look no further than active deal flow and hot cash rolling in. The new regulations are all about bringing efficiency to their investment in China, industry insiders say.

Regulation Deals

Deal-Making Darling Among Latest To Retract China NDAs

Very few people doubt about what China FDA can do to reduce its notorious drug approval backlog, the agency's actual moves and impact to the industry, however, is shocking to many. Meanwhile, a rigorous clinical data review has been expanded to Beijing and Shanghai with local FDA involved.

BioPharmaceutical China
See All